On September 21, GENSCRIPT BIO rose 3.61% in regular trading, trading at HK$40.94/share, with turnover of HK$265 million. The stock extended its recent rally, approaching JP Morgan's target price of HK$41.

On the news front, the company recently announced a collaboration with Eli Lilly's AI-driven drug discovery platform Lilly TuneLab, under which GENSCRIPT BIO will provide wet laboratory services at preferential rates to TuneLab participants, converting AI predictions into biological validation data. This deal further expands the company's footprint in the fast-growing AIDD ecosystem. JP Morgan reiterated its Overweight rating and HK$41 target price, citing sustained AIDD order momentum, robust capacity utilization, and accelerating delivery cycles.

Fundamentally, the company reported H1 revenue of US$404 million, up 27.3% year-over-year, with adjusted net profit surging 203.3%. The life sciences segment grew 28.8%, driven by AI-powered drug discovery and antibody drug demand. The broader CXO sector also showed strong upward momentum, with industry peers WUXI BIO up 3.87%, WUXI APPTEC up 2.90%, and XTALPI up 2.93%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)